Retrospective Cohort Study

Clinical evaluation of endoscopic resection for treatment of large gastric stromal tumors

Yuan-Yuan Xiang, Yuan-Yuan Li, Ling Ye, Yin Zhu, Xiao-Jiang Zhou, You-Xiang Chen, Guo-Hua Li

Abstract

BACKGROUND
Gastric stromal tumor is a digestive tract mesenchymal tumor with malignant potential, and endoscopic techniques have been widely used in the treatment of gastric stromal tumors, but there is still controversy over their use for large gastric stromal tumors (≥3 cm).

AIM
To evaluate the clinical long-term efficacy and safety of endoscopic resection for large (≥3 cm) gastric stromal tumors.

METHODS
All patients who underwent endoscopic resection or surgery at our hospital from 2012 to 2017 for pathologically confirmed gastric stromal tumor with a maximum diameter of ≥3 cm were collected. The clinical data, histopathologic characteristics of the tumors, and long-term outcomes were recorded.

RESULTS
A total of 261 patients were included, including 37 patients in the endoscopy group and 224 patients in the surgical group. In the endoscopy group, the maximum tumor diameter was 3-8 cm; the male: Female ratio was 21:16; 34 cases had low-risk tumors, 3 had intermediate-risk, and 0 had high-risk; the mean follow-up time was 30.29 ± 19.67 mo, no patient was lost to follow-up, and no patient received chemotherapy after operation; two patients with recurrence had low-risk stromal tumors, and neither had complete resection under endoscopy. In the surgical group, the maximum tumor diameter was 3-22 cm; the male: Female ratio was 121:103; 103 cases had low-risk tumors, 75 had intermediate-risk, and 46 had high-risk; the average follow-up time was 38.83 ± 21.50 mo, 53 patients were lost to follow-up, and 8 patients had recurrence after operation (6 cases had high-risk tumors, 1 had intermediate-risk, and 1 had low-risk). The average tumor volume of the endoscopy group was 26.67 ± 26.22 cm³ (3.75-120), all of
which were less than 125 cm\(^3\). The average volume of the surgical group was 273.03 ± 609.74 cm\(^3\) (7-4114). Among all patients with a tumor volume < 125 cm\(^3\), 7 with high-risk stromal tumors in the surgical group (37.625 cm\(^3\) to 115.2 cm\(^3\)) accounted for 3.8% (7/183); of those with a tumor volume < 125 cm\(^3\), high-risk patients accounted for 50% (39/78). We found that 57.1% (12/22) of patients with high-risk stromal tumors also had endoscopic surface ulcer bleeding and tumor liquefaction on ultrasound or abdominal computed tomography; the ratio of tumors positive for both in high-risk stromal tumors with a volume < 125 cm\(^3\) was 60% (3/5).

**CONCLUSION**

Endoscopic treatment is safe for 95.5% of patients with gastric stromal tumors with a tumor diameter ≥ 3 cm and a volume of < 125 cm\(^3\) without endoscopic surface ulcer bleeding or CT liquefaction.

**Key words:** Endoscopic resection; Surgery; Gastric stromal tumor; Clinical evaluation

©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** This study mainly analysed the clinical data of endoscopic resection or surgical treatment of large (≥ 3 cm) gastric stromal tumors from January 2012 to December 2017 at our hospital. The endoscopy group had no high-risk stromal tumors, while patients with the same size tumors were considered high risk in the surgical group. The maximum tumor diameter was significantly larger in the surgical group than in the endoscopy group. A total of 22 patients had tumors with a volumes < 125 cm\(^3\) without liquefaction or surface ulcer bleeding, including 1 high-risk patient.

**Citation:** Xiang YY, Li YY, Ye L, Zhu Y, Zhou XJ, Chen YX, Li GH. Clinical evaluation of endoscopic resection for treatment of large gastric stromal tumors. *World J Clin Cases* 2019; 7(7): 830-838

**URL:** https://www.wjgnet.com/2307-8960/full/v7/i7/830.htm

**DOI:** https://dx.doi.org/10.12998/wjcc.v7.i7.830

**INTRODUCTION**

Gastric stromal tumor is a digestive tract mesenchymal tumor with malignant potential. Studies\(^{[1]}\) have reported that this will increase the psychological burden of patients and the possibility of deterioration of gastric stromal tumor, because some researchers\(^{[2]}\) believe that small gastric stromal tumor may also be malignant, and the size of gastric stromal tumor may increase during long-term follow-up. Although the NCCN\(^{[3]}\) guidelines do not recommend immediate surgical treatment for gastric stromal tumors, researchers such as Yegin \textit{et al.}\(^{[4]}\) believe that once gastrointestinal stromal tumors are suspected, they should be treated by surgical operation or endoscopic resection. In the past, surgical resection is considered to be the standard treatment for gastrointestinal stromal tumors (GISTs), but open surgery is more traumatic, the intraoperative complications are greater, the surgical field is not obvious, and the amount of bleeding is increased. With the development of endoscopic techniques, the use of endoscopy to completely remove gastric stromal tumors has become possible, and the long-term efficacy of endoscopic treatment of gastric stromal tumors < 3 cm in diameter has been determined\(^{[5-7]}\). However, the safety and efficacy of endoscopic treatment of large gastric stromal tumors (≥ 3 cm) remains controversial and few studies focusing on the comparison between endoscopic and surgical methods have been published\(^{[8-11]}\). Therefore, the aim of this retrospective study was to evaluate the clinical long-term efficacy and safety of endoscopic resection for large (≥ 3 cm) GISTs in the stomach.

**MATERIALS AND METHODS**

**Patients**
All patients who underwent endoscopic resection or surgery at our hospital from 2012 to 2017 for pathologically confirmed gastric stromal tumor with a maximum diameter of ≥ 3 cm were collected. The clinical data, intraoperative conditions, pathology, oral chemotherapy, and follow-up data were analysed.

Pathological evaluation
For the evaluation of postoperative GIST biological behavior, the improved NIH classification system\(^1\) was adopted for risk classification.

Follow-up methods
Tumor recurrence was defined as local gastric muscular lesions found on abdominal computed tomography (CT) or endoscopic ultrasonography, or gastric stromal tumors identified at the same location in surgery.

Statistical analysis
All statistical analyses were performed using SPSS 17.0 software. Continuous variables are expressed as the mean ± SD, and categorical data are displayed as numbers (n) and percentages (%), and compared using the \(X^2\) test. The statistical methods of this study were reviewed by Gui-Lian Lan.

RESULTS
A total of 261 patients were included, including 37 patients in the endoscopy group and 224 patients in the surgical group. In the endoscopy group, the maximum tumor diameter was 3-8 cm; 34 cases had low-risk tumors, 3 had intermediate-risk, and 0 had high-risk; the mean follow-up time was 30.29 ± 19.67 mo (range, 7-76), no one was lost to follow-up, and no patient had chemotherapy after operation; two patients had recurrence, both of whom had low-risk stromal tumors and did not undergo complete endoscopic resection. In the surgical group, the largest tumor diameter was 3-22 cm; 103 patients had low-risk tumors, 75 had intermediate-risk, and 46 had high-risk; the average follow-up time was 38.83 ± 21.50 mo (range: 7-78 mo); a total of 53 patients were lost to follow-up, 79 patients received oral chemotherapeutic drugs, and 8 patients had recurrence after operation (6 cases had high-risk tumors, 1 had intermediate-risk, and 1 had low-risk) (Table 1).

We found that the maximum tumor diameter was significantly larger in the surgical group than in the endoscopy group, and the number of patients with high-risk stromal tumors was far greater in the surgical group than in the endoscopy group \((P < 0.05)\). The number of patients taking oral chemotherapy drugs was far greater in the surgical group than in the endoscopy group \((P < 0.01)\). The recurrence rate was similar between the endoscopy group and the surgical group (5.4% vs 4.7%, \(P > 0.05)\), but the endoscopy group had no high-risk stromal tumors, while patients with the same size tumors were considered high risk in the surgical group. We hypothesized that this finding may be related to the tumor volume. Therefore, we performed an analysis based on the volume of tumor.

According to the tumor volume analysis, we found that the average tumor volume of the endoscopy group was 26.67 ± 26.22 cm\(^3\) (range, 3.75-120), all of which were less than 125 cm\(^3\). The average volume of the surgical group was 273.03 ± 609.74 cm\(^3\) (range, 7-4114), and 78 cases had a tumor volume ≥ 125 cm\(^3\), with the intermediate-risk and high-risk stromal tumors each accounting for 50% (39/78) of these tumors. Seven patients with a tumor volume < 125 cm\(^3\) also had high-risk stromal tumors. The tumor volumes of the endoscopy group were significantly smaller than those of the surgical group \((P < 0.05)\). Among all patients with a tumor volume < 125 cm\(^3\), only seven patients in the surgical group had high-risk stromal tumors (37.625 cm\(^3\) to 115.2 cm\(^3\)), accounting for 3.8% (7/183); of tumors with a volume < 125 cm\(^3\), high-risk tumors accounted for 50% (39/78) (Table 2).

Therefore, we found that both patients with a tumor volume ≥ 125 cm\(^3\) and < 125 cm\(^3\) have high-risk gastric stromal tumors. The pathological grade of tumor cannot be determined according to the volume of tumor. Therefore, how should we assess the pathological grade of gastric stromal tumors before surgery?

We analysed whether preoperative endoscopic findings of different pathological grades of gastric stromal tumors showed ulcer haemorrhage on the surface of the tumor and whether there was tumor liquefaction on abdominal CT or ultrasound. We found that the rates of patients who were positive for both were 57.1% in the high-risk group (12/22), 12.7% (6/47) in the intermediate-risk group, and 2.1% (2/97) in the low-risk stromal tumor group; there were statistically significant differences among the three and between any two groups \((P < 0.01)\). The percentage of patients with simple surface ulcer bleeding was 33.3% (7/21) in the high-risk group, 46% (23/50) in
### Table 1 Data on gastric stromal tumors of different sizes

| Maximum diameter of the tumor | Pathological grade (n) | Targeted drugs (n) | Recurrence or metastasis (n) |
|------------------------------|------------------------|--------------------|-----------------------------|
|                              | Endoscopy | Surgery | Endoscopy | Surgery | Endoscopy | Surgery |
| 3-5 cm                       | Low risk (115) | 28 | 87 | 0/28 | 4/69 | 1/28 | 0/69 |
|                              | Moderate risk (8) | 1 | 7 | 0/1 | 5/7 | 0 | 1/7 |
|                              | High risk (1) | 0 | 1 | 0 | Lost to follow-up | 0 | Lost to follow-up |
| 5-10 cm                      | Low risk (22) | 6 | 16 | 0/6 | 0/12 | 1/6 | 1/12 |
|                              | Moderate risk (69) | 2 | 67 | 0/2 | 34/46 | 0 | 0/46 |
|                              | High risk (15) | 0 | 15 | 0 | 12/14 | 0 | 3/14 |
| ≥ 10 cm                      | Low risk (0) | 0 | 0 | 0 | 0 | 0 | 0 |
|                              | Moderate risk (1) | 0 | 1 | 0 | 1/1 | 0 | 0/1 |
|                              | High risk (30) | 0 | 30 | 0 | 21/22 | 0 | 3/22 |
| Total                        | 261 | 224 | 0/37 | 79/171 | 2/37 | 8/171 |

P-value

*P < 0.05: Endoscopy vs Surgery in high-risk patients.

*P < 0.01: Endoscopy vs Surgery in patients receiving targeted drugs.

---

**DISCUSSION**

GISTs account for 1% to 2% of gastrointestinal tumors\(^{13}\). They can occur in any part of the gastrointestinal tract, and the most common part is the stomach (50%-60%)\(^{14}\). With the development of endoscopic techniques in recent years, several studies have demonstrated the safety and efficacy of different endoscopic methods for treating small GISTs\(^{15-20}\). However, only a few data are available for the application of endoscopic methods to large-size tumors\(^{21-25}\) and their follow-up periods were relatively short (range, 3-73 mo), so the long-term efficacy and safety of endoscopic treatment of large gastric stromal tumors remain unclear. This study mainly analysed the clinical data of endoscopic resection or surgical treatment of large (≥ 3 cm) gastric stromal tumors from January 2012 to December 2017 at our hospital, as well as the long-term efficacy of endoscopic resection for large gastric stromal tumors.

Of the 261 included patients, 37 were in the endoscopy group and 224 were in the surgical group. In the endoscopy group, the maximum diameter was 3-8 cm; 34 patients had low-risk tumors, 3 had intermediate-risk, and no patient had high-risk; the intermediate-risk group, and 29.8% (29/97) in the low-risk group; there was no statistically significant difference among the three groups (P = 0.15 > 0.05). There were no high-risk patients with liquefaction alone, while 20% (10/50) and 11.3% (11/97) of intermediate-risk and low-risk patients had liquefaction alone; there was no statistically significant difference among the three groups (P = 0.62 > 0.05). A total of 22 patients had tumors with a volume of less than 125 cm\(^3\) without liquefaction or surface ulcer bleeding, including 1 high-risk (4.5%, 1-22) and 21 (95.5%, 21/22) low or medium-risk stromal tumors. Of seven patients with high-risk stromal tumors < 125 cm\(^3\), 60% (3/5) had endoscopic surface ulcer bleeding and tumor liquefaction on abdominal CT or ultrasound (Table 3).

Two patients with recurrence in the endoscopic group had low-risk stromal tumors (one patient had a maximum diameter of 3 cm and a volume of 18.75 cm\(^3\) and was followed for 6 mo; the other patient had a maximum diameter of 5 cm and a volume of 37.5 cm\(^3\) and was followed for 6 mo); neither was treated with oral chemotherapy and was completely removed under endoscopy. In the surgical group, 8 patients had recurrence (one was metastatic), including 6 cases of high-risk stromal tumors, 1 case of intermediate-risk stromal tumor, and 1 case of low-risk stromal tumor. Among them, six patients with high-risk stromal tumors had a maximum tumor size of 7-20 cm and a volume of 40-3840 cm\(^3\), five patients received oral chemotherapy (6-21 mo), and the follow-up period was 6-35 mo. One patient with an intermediate-risk stromal tumor had a maximum diameter of 4 cm and a volume of 40 cm\(^3\) and was followed for 17 mo without oral chemotherapy. One patient with a low-risk stromal tumor had a maximum diameter of 5 cm and a volume of 56.25 cm\(^3\) and was followed for 34 mo without oral chemotherapy (Table 4).
### Table 2 Data for gastric stromal tumors of different volumes

| Maximum diameter of the tumor | Pathological grade (n) | Targeted drugs (n) | Recurrence or metastasis (n) |
|------------------------------|------------------------|-------------------|-----------------------------|
|                              | Endoscopy | Surgery | Endoscopy | Surgery | Endoscopy | Surgery |
| < 27 cm³                     | Low risk   | 24      | 39       | 0/24    | 1/24     | 1/24     | 0/26     |
|                              | Moderate risk | 1      | 2        | 0/1     | 2/2      | 0/1      | 0/2      |
|                              | High risk   | 0      | 0        | 0       | 0        | 0        | 0        |
| 27-125 cm³                   | Low risk   | 10     | 64       | 0/10    | 4/52     | 1/10     | 1/52     |
|                              | Moderate risk | 2    | 34       | 0/2     | 20/28    | 0/2      | 1/28     |
|                              | High risk   | 0      | 7        | 0       | 5/6      | 0        | 2/6      |
| 125-1000 cm³                 | Low risk   | 0      | 0        | 0       | 0        | 0        | 0        |
|                              | Moderate risk | 0    | 39       | 0       | 20/26    | 0        | 0/26     |
|                              | High risk   | 0      | 24       | 0       | 18/21    | 0        | 2/21     |
| ≥ 1000 cm³                   | Low risk   | 0      | 0        | 0       | 0        | 0        | 0        |
|                              | Moderate risk | 0    | 0        | 0       | 0        | 0        | 0        |
|                              | High risk   | 0      | 15       | 0       | 9/10     | 0        | 2/10     |
| Total                        | 261       | 224    | 0/37     | 79/171  | 2/37     | 8/171    |

P-value

\( ^{*} P < 0.05 \)

\( ^{b} P < 0.01 \)

\( 0.693 \)

the average follow-up time was 30.29 ± 19.67 mo (range, 7-76 mo), none of the patients were lost to follow-up, and no patient received oral chemotherapeutic drugs; two patients had recurrence, both of whom had low-risk stromal tumors and did not undergo complete endoscopic resection. In the surgical group, the largest tumor diameter was 3-22 cm, and 31 tumors were ≥ 10 cm; 103 patients had low-risk tumors, 75 had intermediate-risk, and 46 had high-risk; the average follow-up time was 38.83 ± 21.50 mo (7-78 mo), 53 patients were lost to follow-up, and 8 patients had recurrence after operation (6 cases were high-risk tumors, 1 was intermediate-risk, and 1 was low-risk).

We found that the maximum tumor diameter in the surgical group was much larger than that in the endoscopy group, and there were far more high-risk patients than in the endoscopy group, but the endoscopy group had no high-risk patients, while patients with the same size tumors were considered high-risk patients in the surgical group. We hypothesized that this finding was likely related to the volume of the tumor, and thus we performed further analysis based on the volume of tumor.

The average tumor volume in the endoscopy group was 26.67 ± 26.22 cm³ (3.75-120), all less than 125 cm³, and no one was at high-risk. The average tumor volume in the surgical group was 273.03 ± 609.74 cm³ (7-4114). The tumor volumes of the endoscopy group were smaller than those of the surgical group. Among patients with a tumor volume < 125 cm³, 7 had high-risk tumors (37.62 cm³-115.2 cm³), while among 78 patients with a tumor volume > 125 cm³, intermediate- and high-risk stromal tumors each accounted for 50% (39/78). Both patients with a tumor volume ≥ 125 cm³ and < 125 cm³ had high-risk gastric stromal tumors. There was no high-risk stromal tumor with a volume < 125 cm³ in the endoscopy group. The pathological grade of the tumor cannot be determined according to the volume of tumor. We then asked, how should we determine the pathological grade of the gastric stromal tumor before surgery?

Previous studies have reported that endoscopic tumor ulcer haemorrhage and tumor liquefaction observed by ultrasound or abdominal CT may be related to the malignant degree of gastric stromal tumors. Thus, we analysed the presence or absence of tumour surface ulcer bleeding and whether there was tumour liquefaction on ultrasound or abdominal CT in patients with different pathological grades of gastric stromal tumors. We found that the positive rate for both was 57.1% (12/21) with high-risk tumors, and intermediate-risk and low-risk tumors accounted for 12.7% (6/47) and 2% (2/97), respectively; there were statistically significant differences among the three and between any two of groups (P < 0.01, P < 0.01, P < 0.05, and P < 0.01). The proportion of high-risk patients with simple surface ulcer bleeding was 33.3% (7/21), and the intermediate-risk and low-risk patients accounted for 46% (23/50) and 29.8% (29/97), respectively; there was no significant difference among the three groups (P = 0.15 > 0.05). No high-risk patients had liquefaction alone, while the proportion of intermediate-risk and low-risk patients with simple liquefaction was 20% (10/50) and 11.3% (11/97), respectively; there was no statistically significant difference among the three groups (P = 0.62 > 0.05). Therefore,
patients with endoscopic tumor surface ulcer bleeding and tumor liquefaction on ultrasound or abdominal CT are considered to have a high possibility of malignant stromal tumor, which should not be excluded from endoscopic treatment.

In our study, of 22 patients with a tumor volume < 125 cm³ and no surface ulcer bleeding or tumor liquefaction, 1 (4.5%, 1/22) had a high-risk stromal tumor, and 21 (95.5%, 21/22) had low-risk and intermediate-risk stromal tumors. Of 7 patients with high-risk stromal tumors < 125 cm³, 3 (60%, 3/5) had endoscopic surface ulcer bleeding and tumor liquefaction on abdominal CT or ultrasound. Two patients in the endoscopic group recurred due to incomplete tumor removal; thus, we believe that endoscopic complete resection is safe for 95.5% of patients with a tumor volume < 125 cm³ without surface ulcer haemorrhage or tumor liquefaction. Of all patients with a tumor volume ≥ 125 cm³, the high-risk and intermediate-risk groups accounted for 50% (39/78). Therefore, we found that patients with a tumor volume ≥ 125 cm³ had a high probability of high risk stromal tumor (50%) and were not suitable for endoscopic treatment. All patients with a maximum diameter of ≥ 10 cm accounted for 96.7% (30/31) of the high-risk group; therefore, they are not suitable for endoscopic resection. However, in the endoscopic group, there was no tumor with a maximum diameter ≥ 10 cm, a volume of ≥ 125 cm³, and a classification of high risk, thus, the safety of endoscopic treatment remains unclear. Therefore, a larger multi-center study is needed to confirm these findings.

Research reports[28] indicate that the use of chemotherapy before surgery can reduce the tumor volume and the scope of surgery to improve the overall cure rate. For GISTs of important organs, it can retain the structure and function of organs to the utmost extent and reduce the risk of tumor rupture and bleeding. It is currently recommended that the target drug treatment time should be more than 1 year for mid-risk patients, and more than 3 years for high-risk patients; patients at a high risk of tumor rupture should extend the medication time[29]. In our study, 78 (29.8%) patients were in the intermediate-risk group, including 3 patients in the endoscopy group and 75 patients in the surgical group. Among them, 3 intermediate-risk patients in the endoscopic group were not treated with oral chemotherapy, and no recurrence or metastasis was observed during the follow-up period. There were 14 intermediate-risk patients who did not take oral chemotherapeutic drugs after surgery, but only 1 patient had recurrence (7.1%, 1/14). Therefore, we believe that oral chemotherapy drugs may not be needed for intermediate-risk patients, but larger sample studies are still needed for further confirmation.

In summary, this study provided several important findings. First, prior to endoscopic treatment of gastric stromal tumors with a maximum diameter ≥ 3 cm, tumor volume should be evaluated preoperatively by ultrasound. Second, endoscopic treatment was found safe for 95.5% of patients with gastric stromal tumors having a tumor diameter ≥ 3 cm and a tumor volume < 125 cm³ without endoscopic surface ulcer bleeding or CT liquefaction. Third, endoscopic treatment should not be

---

**Table 3 Characteristics of preoperative examination of gastric stromal tumors with different pathological grades**

| Pathological grade | Tumor volume | Ulcer bleeding | Liquefaction | None³ | Both⁴ |
|--------------------|--------------|----------------|-------------|-------|-------|
| Low risk           | < 27 cm³ (63)| 11/49          | 1/49        | 36/49 | 1/49  |
|                    | 27-125cm³ (74)| 18/48          | 10/48       | 19/48 | 1/48  |
|                    | ≥ 1000 cm³ (0)| 0              | 0           | 0     | 0     |
| Moderate risk      | < 27 cm³ (3) | 1/3            | 0/3         | 2/3   | 0/3   |
|                    | 27-125cm³ (56)| 17/28          | 7/28        | 2/28  | 2/28  |
|                    | 125-1000 cm³ (39)| 5/19           | 3/19        | 7/19  | 4/19  |
|                    | ≥ 1000 cm³ (0)| 0              | 0           | 0     | 0     |
| High risk (46)     | < 27 cm³ (0) | 0              | 0           | 0     | 0     |
|                    | 27-125cm³ (7) | 1/5            | 0/5         | 1/5   | 3/5   |
|                    | 125-1000 cm³ (24)| 6/14           | 0/14        | 1/14  | 7/14  |
|                    | ≥ 1000 cm³ (15)| 0/2            | 0/2         | 0/2   | 2/2   |

P-value: 1.15, 0.62, *P < 0.05, **P < 0.01.

None³: No ulcer bleeding or tumor liquefaction. Both⁴: Ulcer bleeding and tumor liquefaction. Low-risk stromal tumors vs medium-risk stromal tumors, moderate risk vs high risk, and low risk vs high risk were found to be statistically significant (*P < 0.01, **P < 0.05, ***P < 0.01).
Table 4  Clinical data for 10 patients with recurrence

| Surgical method | Maximum diameter | Volume | Pathological grade | Operation data | Follow-up time (mo) | Medication time (mo) | Liquefaction | Ulcer bleeding |
|-----------------|------------------|--------|--------------------|----------------|---------------------|---------------------|--------------|----------------|
| Endoscopy group | 5                | 37.5   | Low risk           | 2012/3/26      | 41                  | No                  | No           | No             |
|                 | 3                | 18.75  | Low risk           | 2017/10/27     | 6                   | No                  | No           | No             |
| Surgery group   | 5                | 56.25  | Low risk           | 2014/12/9      | 34                  | No                  | No           | Yes            |
|                 | 4                | 40     | Moderate risk      | 2017/2/11      | 17                  | No                  | Yes          | No             |
|                 | 7                | 147    | High risk          | 2015/1/14      | 12                  | 12                  | No           | Yes            |
|                 | 7.5              | 56.25  | High risk          | 2016/6/1       | 21                  | 21                  | Yes          | Unknown        |
|                 | 8                | 96     | High risk          | 2017/12/1      | 6                   | 6                   | Yes          | Yes            |
|                 | 14               | 700    | High risk          | 2015/8/7       | 35                  | No                  | Yes          | Yes            |
|                 | 18.5             | 1572.5 | High risk          | 2015/4/17      | 24                  | 18                  | Yes          | Unknown        |
|                 | 20               | 3840   | High risk          | 2016/2/23      | 11                  | 6                   | Yes          | Unknown        |

performed for patients with gastric stromal tumors with a maximum diameter ≥ 10 cm and a volume ≥ 125 cm³. Lastly, oral chemotherapeutics may not be needed for patients with intermediate-risk stromal tumors.

ARTICLE HIGHLIGHTS

Research background
Gastrointestinal stromal tumors (GISTs), first proposed by Mazur et al in 1983, are a group of gastrointestinal stromal tumors with malignant differentiation potential, which are not sensitive to radiotherapy and chemotherapy. The pathological examination technique is difficult to popularize widely, so it is recommended to follow the diameter < 2 cm at present, while the diameter > 2 cm is treated surgically, but the malignant change and metastasis may occur during the long-term follow-up period. Therefore, surgical resection is the only way to treat GISTs, mainly including traditional open surgery, laparoscopic surgery, and endoscopic digestive surgery. Past transmission Open laparotomy is the first choice for the treatment of gastrointestinal stromal tumors, but for the patients with smaller diameter of the tumor, the surgical trauma is greater. In addition, the perioperative mortality of elderly patients can be as high as 1% or more. At the same time, the traditional open operation time is long, intraoperative bleeding is much, and the operation cost is expensive. Laparoscopic surgery has been proved to be a safe and effective method for the treatment of gastric stromal tumors with a diameter ≤ 5 cm, and it is also effective in the treatment of gastric stromal tumors with a tumor diameter > 5 cm. However, there are some limitations to the microstromal tumors whose diameter is smaller than 1 cm and the gastric stromal tumors with special location. If it is difficult to remove the large tumor through the orifice, it is necessary to cut open the abdominal wall or prolong the surgical incision. Moreover, it is difficult to expose and operate the tumors near the gastric cardia and the great curvature of the stomach body near the fundus of the stomach. In recent years, with the continuous development of endoscopic technology and endoscopic instruments, endoscopic resection of gastric GISTs is possible. Many studies have shown that endoscopic resection is safe and effective in treating gastric GISTs. It provides an effective minimally invasive method for the treatment of gastric stromal tumors. However, endoscopic resection is prone to major complications, such as bleeding, perforation, and positive margin. There are still doubts about the safety and efficacy of endoscopic treatment for gastric stromal tumors. In recent years, there have been many reports about the clinical evaluation of endoscopic treatment of gastric stromal tumors, which confirmed the efficacy and safety of endoscopic treatment of < 3 cm gastric stromal tumors. However, there are few reports about endoscopic treatment of large gastric stromal tumors (≥ 3 cm). The efficacy and safety of endoscopic treatment for < 5 cm gastric stromal tumors were confirmed, but the follow-up time was short and the sample size was small. More literature reports are needed to further confirm the long-term efficacy of endoscopic treatment for large stromal tumors of the stomach.

Research motivation
The purpose of this study was to collect the clinical and pathological data of all patients diagnosed with gastric stromal tumors with the largest diameter ≥ 3 cm at our hospital during the last six years from 2012 to 2017, who were treated by endoscopy or surgery. The long-term curative effect was evaluated by follow-up to evaluate the long-term efficacy of endoscopic treatment of large gastric stromal tumors, and to provide a direction for the choice of surgical methods for large gastric stromal tumors in the future.

Research objectives
The main purpose of this study was to observe the long-term efficacy of endoscopic treatment of gastric macrostromal tumors, and to reduce the pain associated with surgical treatment in patients with large gastric stromal tumors. More patients with large stromal tumors of the
stomach can enjoy the benefits of minimally invasive surgery and improve the quality of life.

**Research methods**

From 2012 to 2017, the clinical data of all patients with large stromal tumor of the stomach treated by endoscopy or surgery were analyzed and a long-term follow-up was carried out. In this study, the chi-square test was used to test the statistical differences between groups, which clearly confirmed the differences between the two groups.

**Research results**

In this study, we found that endoscopic therapy can be used to treat large gastric stromal tumors, but it needs to meet certain conditions, and should be evaluated according to the results of preoperative ultrasound. There is controversy about whether endoscopic treatment of large gastric stromal tumors can be performed in previous studies. This study provides a good answer to the circumstances in which patients with large stromal tumors of the stomach can be treated by endoscopy. It provides a direction for the treatment of large stromal tumors of the stomach in the future.

**Research conclusions**

In this study, we found that the volume of gastric stromal tumor treated by endoscopy is smaller than that by surgical treatment. For patients with moderate-risk stromal tumors, oral chemotherapeutic drugs may not be needed, and endoscopy can be used to treat large gastric stromal tumors. However, certain conditions need to be met. Endoscopic treatment is safe for 95.5% of patients with gastric stromal tumors with a diameter ≥ 3 cm and a volume < 125 cm³ without endoscopic surface ulcer bleeding or CT liquefaction. This study will provide a direction for the choice of treatment methods for patients with large stromal tumors of the stomach in clinical work.

**Research perspectives**

There are many other aspects to judge the pathological grade of gastric stromal tumors before operation. We can continue to study more factors affecting the pathological grade of gastric stromal tumors on the basis of this study in the future. This study is a retrospective single-center study. There were no high-risk stromal tumors in the endoscopy group and no patients with a maximum tumor diameter ≥ 10 cm or volume ≥ 125 cm³. In the future, a multicenter prospective study of larger stromal tumors of the stomach could be attempted, to further explore the long-term safety and efficacy of endoscopic treatment for large stromal tumors of the stomach.

**ACKNOWLEDGEMENTS**

I show my sincere gratitude to my supervisor, professor Guo-Hua Li, for proposing this novel and clinically significant topic and guiding me to collect and analyze the data. At the same time, I would like to thank professor You-Xiang Chen, Xiao-Jiang Zhou, and other professors for their valuable comments on my article. In addition, I would like to thank The First Affiliated Hospital of Nanchang University for providing me with an excellent data collection platform.

**REFERENCES**

1. Koga T, Hirayama Y, Yoshiya S, Taketani K, Nakanoko T, Yoshida R, Minagawa R, Kai M, Kajiyama K, Akaoshiki K, Maehara Y. Necessity for resection of gastric gastrointestinal stromal tumors ≤ 20 mm. *Anticancer Res* 2015; 35: 2341-2344 [PMID: 25862898]

2. Fang YJ, Cheng TY, Sun MS, Yang CS, Chen JH, Liao WC, Wang HP. Suggested cutoff tumor size for management of small EUS-suspected gastric gastrointestinal stromal tumors. *J Formos Med Assoc* 2012; 111: 88-93 [PMID: 22370287 DOI: 10.1016/j.jfma.2011.01.002]

3. Demetri GD, von Mehren M, Antonescu CR, DeMatteo RP, Ganjoo KN, Maki RG, Pisters PW, Raut CP, Riedel RF, Schueette S, Sundar HM, Trent JC, Wayne JD. NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors. *J Natl Compr Canc Netw* 2010; 8 Suppl 2: S1-41; quiz S42-4 [PMID: 20457867]

4. Yegin EG, Duman DG. Small EUS-suspected gastrointestinal stromal tumors of the stomach: An overview for the current state of management. *Endosc Ultrasound* 2016; 5: 69-77 [PMID: 27080604 DOI: 10.1093/2303/9027.180460]

5. Jain D, Mahmood E, Desai A, Singhal S. Endoscopic full thickness resection for gastric tumors originating from the muscularis propria. *World J Gastrointest Endosc* 2016; 8: 489-495 [PMID: 27499831 DOI: 10.4253/wjge.v8.i14.489]

6. Meng Y, Li W, Han L, Zhang Q, Gong W, Cai J, Li A, Yan Q, Lai Q, Ju J, Bai L, Liu S, Li Y. Long-term outcomes of endoscopic submucosal dissection versus laparoscopic resection for gastric stromal tumors less than 2 cm. *J Gastroenterol Hepatol* 2017; 32: 1693-1697 [PMID: 28320962 DOI: 10.1111/jgh.13768]

7. Wang S, Shen L. Efficacy of Endoscopic Submucosal Excavation for Gastric Stromal Tumors in the Cardia. *Surg Laparosc Endosc Percutan Tech* 2016; 26: 493-496 [PMID: 27846180 DOI: 10.1097/SLE.0000000000000316]

8. Meng Y, Cao C, Song S, Liu Y, Liu S. Endoscopic band ligation versus endoscopic submucosal dissection and laparoscopic resection for small gastric stromal tumors. *Surg Endosc* 2016; 30: 2873-2878 [PMID: 26490768 DOI: 10.1007/s00464-015-4571-5]

9. Wu CR, Huang LY, Guo J, Zhang B, Cui J, Sun CM, Jiang LX, Wang ZH, Ju AH. Clinical Control Study
of Endoscopic Full-thickness Resection and Laparoscopic Surgery in the Treatment of Gastric Tumors Arising from the Muscularis Propria. *Clin Med (Engl)* 2015; 128: 1455-1459 [PMID: 26021500 DOI: 10.1038/0346-6999.157651]

10 Huang LY, Cui J, Wu CR, Zhang B, Jiang LX, Xian XS, Lin SJ, Xu N, Cao XL, Wang ZH. Endoscopic full-thickness resection and laparoscopic surgery for treatment of gastric stromal tumors. *World J Gastroenterol* 2014; 20: 8253-8259 [PMID: 25099400 DOI: 10.3748/wjg.v20.i25.8253]

11 Dong HY, Wang YL, Jia XY, Li J, Li GD, Li YQ. Modified laparoscopic intragastric surgery and endoscopic full-thickness resection for gastric stromal tumor originating from the muscularis propria. *Surg Endosc* 2014; 28: 1447-1453 [PMID: 24671370 DOI: 10.1007/s00464-013-3375-8]

12 Joensuu H. Risk stratification of patients diagnosed with gastrointestinal stromal tumor. *Hum Pathol* 2008; 39: 1411-1419 [PMID: 18774375 DOI: 10.1016/j.humpath.2008.06.025]

13 Chandrasekhar V, Ginsberg G. Endoscopic management of gastrointestinal stromal tumors. *Curr Gastroenterol Rep* 2011; 13: 532-539 [PMID: 21931997 DOI: 10.1007/s11894-011-0224-6]

14 Zhou C, Duan X, Zhang X, Hu H, Wang D, Shen J. Predictive features of CT for risk stratifications in patients with primary gastrointestinal stromal tumour. *Eur Radiol* 2016; 26: 3086-3093 [PMID: 26699371 DOI: 10.1007/s00330-015-4172-7]

15 Wang H, Feng X, Ye S, Wang J, Liang J, Mai S, Lai M, Feng H, Wang G, Zhou Y. A comparison of the efficacy and safety of endoscopic full-thickness resection and laparoscopic-assisted surgery for small gastrointestinal stromal tumors. *Surg Endosc* 2016; 30: 3357-3361 [PMID: 26497947 DOI: 10.1007/s00464-015-4612-0]

16 Balde AI, Chen T, Hu Y, Redondo NJD, Liu H, Gong W, Yu J, Zhen L, Li G. Safety analysis of laparoscopic endoscopic cooperative surgery versus endoscopic submucosal dissection for selected gastric gastrointestinal stromal tumors: a propensity score-matched study. *Surg Endosc* 2017; 31: 843-851 [PMID: 27492430 DOI: 10.1007/s00464-016-5042-3]

17 Chen X, Cao H, Wang S, Wang D, Xu M, Piao M, Wang B. Endoscopic submucosal dissection for silent gastric Dieulafoy lesions mimicking gastrointestinal stromal tumors: Report of 7 cases-a case report series. *Medicine (Baltimore)* 2016; 95: e4829 [PMID: 27663399 DOI: 10.1097/MD.0000000000004829]

18 Catalano F, Rodella L, Lombardo F, Silano M, Tanese M, Funni A, Di Fusco MA, de Manzoni G, Trecca A. Endoscopic submucosal dissection in the treatment of gastric stromal tumors: results from a retrospective cohort study. *Gastric Cancer* 2013; 16: 563-570 [PMID: 23271043 DOI: 10.1010/s10120-012-0225-7]

19 Joo MK, Park JJ, Kim H, Koh JS, Lee BJ, Chun HJ, Lee SW, Jung YJ, Mok YJ, Bak YT. Endoscopic versus surgical resection of GI stromal tumors in the upper GI tract. *Gastroendosc* 2016; 83: 318-326 [PMID: 26279298 DOI: 10.1016/j.gie.2015.07.034]

20 Tan Y, Tang X, Guo T, Peng D, Tang Y, Duan T, Wang X, Lv L, Hao J, Liu D. Comparison between submucosal tunneling endoscopic resection and endoscopic full-thickness resection for gastric stromal tumors originating from the muscularis propria layer. *Surg Endosc* 2017; 31: 3376-3382 [PMID: 27864722 DOI: 10.1007/s00464-016-5350-7]

21 He Z, Sun C, Zheng Z, Yu Q, Wang T, Chen X, Cao H, Liu W, Wang B. Endoscopic submucosal dissection of large gastrointestinal stromal tumors in the esophagus and stomach. *J Gastroenterol Hepatol* 2013; 28: 262-267 [PMID: 23190047 DOI: 10.1111/jgh.12056]

22 Biakd A, Wiewiorska-Kozhowska A, Huk J. Endoscopic submucosal dissection of large gastrointestinal stromal tumor arising from muscularis propria. *Clin Gastroenterol Hepatol* 2010; 8: e119-e120 [PMID: 20661338 DOI: 10.1016/j.cgh.2010.06.008]

23 Li QL, Yao LQ, Zhou PH, Xu MD, Chen SY, Zhong YS, Zhang YQ, Chen WF, Ma LL, Qin WZ. Submucosal resection of the esophagea gastrophis junction originating from the muscularis propria layer: a large study of endoscopic submucosal dissection (with video). *Gastrointest Endosc* 2012; 75: 1153-1158 [PMID: 22459663 DOI: 10.1016/j.gie.2012.01.037]

24 Wang F, Fan CQ, Ren W, Zhang X, Li YH, Zhao XY. Endoscopic dissection of large endogenous myogenic tumors in the esophagus and stomach is safe and feasible: a report of 42 cases. *Scand J Gastroenterol* 2011; 46: 627-633 [PMID: 21366494 DOI: 10.3109/03002697.2011.561364]

25 Yu C, Liao G, Fan C, Yu L, Nie X, Yang S, Bai J. Long-term outcomes of endoscopic resection of gastric GISTs. *Surg Endosc* 2017; 31: 4799-4804 [PMID: 28424911 DOI: 10.1007/s00464-017-5557-2]

26 Nishida T, Kawai N, Yamaguchi S, Nishida Y. Submucosal tumors: comprehensive guide for the diagnosis and therapy of gastrointestinal submucosal tumors. *Dig Endosc* 2013; 25: 479-489 [PMID: 23902569 DOI: 10.1111/den.12149]

27 Lei C, Liu L, Wang Q, Wang H. [Treatment and prognosis of 108 patients with high-risk gastrointestinal stromal tumor]. *Zhonghua Wei Chang Wai Ke Za Zhi* 2016; 19: 1300-1304 [PMID: 27928804]

28 ESCM/European Sarcoma Network Working Group. Gastrointestinal stromal tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 2014; 25 Suppl 3: iii21-iii26 [PMID: 25120085 DOI: 10.1093/annonc/mdu255]

29 Rubiño-Casadevall J, Martinez-Trufero J, Garcia-Albeniz X, Calabuig S, Lopez-Pousa A, Del Muro JG, Fra J, Redondo A, Lainez N, Poveda A, Valverde C, De Juan A, Sevilla I, Casado A, Andres R, Cruz J, Martin-Broto J, Maurel J. Spanish Group for Research on Sarcoma (GEIS). Role of surgery in patients with recurrent, metastatic, or unresectable locally advanced gastrointestinal stromal tumors sensitive to imatinib: a retrospective analysis of the Spanish Group for Research on Sarcoma (GEIS). *Ann Surg Oncol* 2015; 22: 2948-2957 [PMID: 25608769 DOI: 10.1245/s10434-014-4360-8]
